Cigna Investments’s CytomX Therapeutics CTMX Stock Holding History

Cigna Investments’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,599	Closed	-$97K	–	668
2020 Q2	$97K	Buy	+11,599	New	+$108K	0.01%	740

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cigna Investments's CTMX Position: Q3 2020 in Review

Cigna Investments sold out of CytomX Therapeutics (CTMX) in Q3 2020, closing a stake of 11,599 shares — an estimated $97K sold.

Cigna Investments first reported a position in CTMX in Q2 2020 and held it in 1 quarter. The position peaked at $97K in Q2 2020. 130 funds tracked by Wall St. Rank hold CTMX as of Q3 2020.

Cigna Investments reported no remaining CytomX Therapeutics position as of Q3 2020 after selling out during the quarter.
Cigna Investments sold 11,599 CytomX Therapeutics shares in Q3 2020, an estimated $97K.
Cigna Investments first reported a position in CytomX Therapeutics in Q2 2020 and held it in 1 quarter.
Cigna Investments's CytomX Therapeutics position peaked at $97K in Q2 2020.
130 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2020.

Based on Cigna Investments's 13F filing for Q3 2020, filed 12 Nov 2020.